Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 17/20 | 0.67 |
| ▸ | EGFR | P00533 | 3/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.58 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.58 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.48 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4764020 | 0.87 | EGFR (0.60) | PRMT5EGFRAURKBINCENPTTBK1 | |
| SCHEMBL4763910 | 0.87 | PRMT5 (0.66) | PRMT5EGFRAURKBINCENP | |
| SCHEMBL4766562 | 0.87 | PRMT5 (0.69) | PRMT5EGFRAURKBINCENPTTBK1 | |
| SCHEMBL4771238 | 0.86 | EGFR (0.59) | PRMT5EGFRAURKBINCENPTTBK1 | |
| SCHEMBL4764456 | 0.85 | PRMT5 (0.66) | PRMT5EGFRAURKBINCENP | |
| SCHEMBL4763947 | 0.83 | PRMT5 (0.64) | PRMT5EGFRAURKBINCENPTTBK1 | |
| SCHEMBL4764558 | 0.81 | EGFR (0.63) | PRMT5EGFRAURKBINCENPTTBK1 | |
| SCHEMBL4766474 | 0.81 | CSF1R (0.46) | PRMT5EGFR | |
| SCHEMBL30571357 | 0.81 | PRMT5 (1.00) | PRMT5EGFR | |
| SCHEMBL4768646 | 0.79 | EGFR (0.61) | PRMT5EGFRAURKBINCENPTTBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1416935-B1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-03-12 | — | — | EP | claimed |
| US-7244729-B2 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2007-07-17 | — | — | US | claimed |
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | BOLD GUIDO (CH) | 2004-12-09 | — | — | US | claimed |
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | claimed |
| EP-1416935-B1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| CN-1538847-A | 4-amino-6-phenyl-pyrrolo [2, 3-d ] pyrimidine derivatives | ��˹��ŵ�� | 2004-10-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | DPYD, DHPS, TYMP | PRMT5 684/4885EGFR 3391/4885AURKB 964/4885 |
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | DPYD, TYMP, TYMS | PRMT5 345/4885EGFR 2694/4885AURKB 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.